Nymox Pharmaceutical reports positive study results

Nymox Pharmaceutical Corp. (Nasdaq: NYMX) announced successful new study results from a long-term Phase 3 trial of the prostate cancer treatment fexapotide sending the stock price soaring $2.02 to close at $4.45.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.